The extra dose in a Mounjaro pen — what it is, and why it matters

You've finished dose four and noticed liquid still in the pen

It happens regularly. You press the button for what should be your last weekly dose, and when you hold the pen up to the light there is still a faint line of liquid visible inside the cartridge. Naturally, the thought crosses your mind: could that be a fifth injection?

The short answer is no, and the reason is straightforward. Pharmaceutical manufacturers are required to include a small volume of overfill in injectable pens to ensure that every labelled dose (all four of them) is delivered accurately. If the pen contained exactly and only four doses' worth of liquid, the final injection would risk being underfilled as a result of air, viscosity variation, or the mechanics of the plunger reaching its stop. The overfill compensates for that. It exists for precision, not generosity.

The Mounjaro KwikPen extra dose question comes up often enough that it is worth being direct: the residual liquid after the fourth injection is not a discrete, measurable fifth dose. Its volume is variable and uncontrolled. Using it would mean injecting an unknown quantity of tirzepatide, which runs against the entire logic of a carefully titrated treatment plan. For a fuller look at whether any usable liquid can genuinely be retrieved, this page on extracting the remaining dose covers the practical reality in more detail.

Why this is more than a technicality

There is a common misconception that the overfill is simply the manufacturer being cautious with their labelling, and that a confident, capable person could just use a fresh needle to draw out what is left. The reality is more nuanced.

The Mounjaro KwikPen is a single-patient, multi-dose device that delivers four injections through the same device mechanism. After the fourth dose, the plunger has reached its designed stopping point. The pen is not designed to be held at an angle, depressed further, or used with a separate syringe to aspirate residual liquid. Doing so introduces risks that are absent from the standard four-dose use: needle-stick exposure, contamination, and, most importantly, an imprecise quantity of tirzepatide entering the body at an unscheduled moment.

Tirzepatide's dosing schedule (starting at 2.5 mg and moving upward under prescriber guidance) is built around predictability. The body adapts to each level before the next begins. An uncontrolled extra dose sits outside that structure entirely. The full Mounjaro guide explains how the titration schedule works and why the steps matter for tolerability.

The NHS patient information for tirzepatide, available at nhs.uk/medicines/tirzepatide, is clear that doses should be taken exactly as directed by your healthcare professional. There is no provision for supplementary injections drawn from pen residue.

What to do if you think your pen ran short

A separate and legitimate concern is when a dose feels like it did not deliver fully, the pen clicked but the window did not move as expected, or you are not confident the injection was complete. That is different from seeking an extra dose, and it deserves a different response.

If you genuinely believe a dose was not administered correctly, contact your prescribing team before your next scheduled injection. Do not attempt to re-dose immediately. At nume, our prescribers are available seven days a week through priority aftercare, precisely for situations like this. A clinician can talk through what happened and advise on the right next step, which is rarely "take another injection today".

For people who are asking about whether the extra dose in the Mounjaro pen can actually be used, or whether there truly is one, the consistent clinical answer is the same: the overfill is not a dose. The pen's design means it cannot reliably be delivered, and the attempt is not worth the risk.

If cost is a factor in why the question is being asked (stretching one pen to five weeks rather than four) it is worth knowing that understanding what drives Mounjaro's UK pricing can help, and that a conversation with your prescriber about whether your current dose is the right one is always more useful than improvising with residual medicine. The free consultation at nume is a good place to start that conversation.

The device, the licence, and your safety

Mounjaro is a Black Triangle medicine, meaning the MHRA keeps it under additional monitoring while post-market safety data continues to accumulate. That monitoring depends, in part, on patients using it as licensed. The NICE appraisal of tirzepatide (TA1026) that underpins its NHS and private use was based on clinical trial data in which participants followed the defined dosing protocol. Using residual pen contents falls outside that protocol and therefore outside the evidence base.

If you have questions about partial doses or how dose changes work in practice, those are conversations for a prescriber rather than a forum. Our clinical team, led by our clinical director, reviews every prescription personally. No algorithm, no auto-renewal. If your treatment plan needs adjusting, that is exactly what the review is for.